IP Library Assignment 021339/0977
Patent Assignment
Reel/Frame 021339/0977

Assignment of Assignor's Interest

Recorded: 2008-08-07 Pages: 9
Assignor
NPS ALLELIX CORP.
Executed: 2008-07-28
Assignee
NPS PHARMACEUTICALS, INC.
550 HILLS DRIVE, THIRD FLOOR, BEDMINSTER, NEW JERSEY, 07921
Covered Properties (97)
Method for Enzymatic Production of Glp-2(1-33) and Glp-2(1-34) Peptides
Patent: 7,781,567 →
Application: 10/997,065 →
Publication: US US20060024778A1
Production of Glucagon-Like Peptide 2
Patent: 7,829,307 →
Application: 10/993,127 →
Publication: US US20050164930A1
Treatment of Short Bowel Syndrome Patients with Colon-In-Continuity
Patent: 7,847,061 →
Application: 11/262,980 →
Publication: US US20060135424A1
Biomarker of Improved Intestinal Function
Application: 11/606,896 →
Publication: US US20070184554A1
Assay System for Glp-2 Receptor Ligands
Patent: 7,498,141 →
Application: 11/607,030 →
Publication: US US20070154959A1
Diaryl-Enynes
Patent: 6,426,364 →
Application: 09/704,225 →
Diaryl-Enynes
Patent: 6,525,085 →
Application: 10/174,226 →
Publication: US US20020169197A1
Diaryl-Enynes
Patent: 6,579,987 →
Application: 10/324,195 →
Publication: US US20030092769A1
Glyt-1 Inhibitors
Patent: 6,667,336 →
Application: 10/077,579 →
Publication: US US20030176489A1
Cloned Glucagon-Like Peptide 2 Receptors
Patent: 6,077,949 →
Application: 08/845,546 →
Intestinotrophic Glucagon-Like Peptide-2 Analogs
Patent: 6,184,201 →
Application: 08/835,538 →
Antagonists of Intestinotrophic Glp-2 Peptides
Patent: 5,994,500 →
Application: 08/683,890 →
Antagonists of Intestinotrophic Glp-2 Peptides
Patent: 6,489,295 →
Application: 09/233,934 →
Ampa-Binding Human GLUR3 Receptors
Patent: 6,413,739 →
Application: 08/896,063 →
Glp-2 Formulations
Patent: 7,056,886 →
Application: 09/750,022 →
Publication: US US20010027180A1
Excretion of Heterologous Proteins from E. Coli
Patent: 5,223,407 →
Application: 07/395,797 →
Excretion of Heterologous Proteins from E. Coli
Patent: 5,646,015 →
Application: 08/439,132 →
Human NR2A Binding Assay
Patent: 6,489,124 →
Application: 08/217,704 →
Ionotropic Human Glutamate Recepyor Subunit NR3
Patent: 6,391,566 →
Application: 08/264,578 →
Ampa-Binding Human GLUR2 Receptors
Patent: 6,399,313 →
Application: 08/439,946 →
Ampa-Binding Human GLUR2 Receptors
Patent: 6,441,155 →
Application: 08/242,344 →
Ampa-Binding Human GLUR4 Receptors
Patent: 6,372,488 →
Application: 08/473,204 →
Polynucleotides Encoding Ampa-Binding Human GLUR4 Receptors
Patent: 5,643,785 →
Application: 08/259,164 →
Ampa-Binding Human GLUR4 Receptors
Patent: 7,071,306 →
Application: 10/121,675 →
Publication: US US20030053993A1
Ampa-Binding Human GLUR4 Receptor Methods
Patent: 6,358,693 →
Application: 08/403,663 →
Ampa-Binding Human GLUR1 Receptors
Patent: 6,406,868 →
Application: 08/216,326 →
Ampa-Binding Human GLUR3 Receptors
Patent: 7,030,221 →
Application: 10/151,003 →
Publication: US US20030032038A1
Ampa-Binding Human GLUR3 Receptors
Patent: 6,403,323 →
Application: 08/257,029 →
Ampa-Binding Human GLUR2 Receptors
Patent: 6,040,175 →
Application: 08/483,327 →
Kainate-Binding, Human Cns Receptors of the EAA4 Family
Patent: 6,376,200 →
Application: 08/249,241 →
Glutamate Receptor (or Eaa Receptor) Polynucleotides and Their Uses
Patent: 6,136,544 →
Application: 08/666,221 →
Kainate-Binding, Human Cns Receptors of the EAA3 Family
Patent: 6,500,624 →
Application: 08/189,738 →
Kainate-Binding Human Cns Glutamate Receptors EAA3C and EAA3D, Dna Enc Oding Them, and Expression of the Dna in Transformed Cells
Patent: 5,547,855 →
Application: 08/405,392 →
Human Cns Receptors of the Nmda-R1 Family
Patent: 6,500,634 →
Application: 08/164,487 →
Kainate-Binding, Human Cns Receptors of the EAA5 Family
Patent: 6,333,161 →
Application: 08/178,019 →
Dna Encoding Kainate-Binding, Human Cns Receptors of the EAA5 Family
Patent: 6,322,999 →
Application: 08/377,503 →
Kainate-Binding, Human Cns Receptors of the EAA2 Family
Patent: 5,981,704 →
Application: 08/822,238 →
Kainate-Binding Human Cns Receptors of the EAA2 Family
Patent: 5,614,406 →
Application: 08/203,676 →
Kainate-Binding Human Cns Receptors of the EAA1 Family
Patent: 5,576,205 →
Application: 08/185,232 →
An Isolated Human Edg-4 Receptor
Patent: 7,052,850 →
Application: 10/084,507 →
Publication: US US20030054452A1
Compounds Having 5-HT6 Receptor Antagonist Activity
Patent: 6,897,215 →
Application: 10/111,404 →
Azaindoles Having Serotonin Receptor Affinity
Patent: 6,686,374 →
Application: 09/636,592 →
Mammalian Edg-7 Receptor Homologs
Patent: 6,566,096 →
Application: 09/731,030 →
Publication: US US20020142375A1
3-Bicycloindole Compounds
Patent: 6,562,809 →
Application: 09/156,496 →
An Isolated Edg-4 Receptor and Polynucletide Encoding Said Receptor
Patent: 6,482,609 →
Application: 09/582,200 →
N-Alkylamino-Indoles for the Treatment of Migraine
Patent: 6,380,242 →
Application: 09/469,327 →
5-Bicycloindole Compounds
Patent: 6,329,390 →
Application: 09/116,946 →
Methods Useful in the Treatment of Bone Resorption Diseases
Patent: 6,284,730 →
Application: 09/125,247 →
Bicyclic Piperidine and Piperazine Compounds Having 5-HT6 Receptor Affinity
Patent: 6,251,893 →
Application: 09/156,495 →
Azaindoles Having Serotonin Receptor Affinity
Patent: 6,191,141 →
Application: 09/373,212 →
Production of Human Parathyroid Hormone from Microorganisms
Patent: 6,146,852 →
Application: 08/461,436 →
Piperidine-Indole Compounds Having 5-HT6 Affinity
Patent: 6,133,287 →
Application: 09/046,669 →
Pyrrolidine-Indole Compounds Having 5-HT6 Affinity
Patent: 6,100,291 →
Application: 09/039,269 →
Essentially Pure Human Parathyroid Hormone
Patent: 5,208,041 →
Application: 07/707,114 →
Mammalian Edg-5 Receptor Homologs
Patent: 6,057,126 →
Application: 08/997,803 →
Isolated Polynucleotide for Novel G-Protein Coupled Receptor
Patent: 6,020,158 →
Application: 08/861,747 →
5-Alkyl Indole Compounds
Patent: 5,998,462 →
Application: 08/767,323 →
5-Cyclo Indole Compounds
Patent: 5,998,438 →
Application: 08/976,103 →
5-Alkenyl and 5-Alkynyl Indole Compounds
Patent: 5,856,510 →
Application: 08/767,322 →
Expression of Human D4 Dopamine Receptors in Stable Cell Lines
Patent: 5,846,823 →
Application: 08/623,471 →
Alkyl-Substituted Compounds Having Dopamine Receptor Affinity
Patent: 5,834,459 →
Application: 08/754,014 →
Selective Template Deletion Method
Patent: 5,830,712 →
Application: 08/597,249 →
Glucagon-Like Peptide-2 Analogs
Patent: 5,789,379 →
Application: 08/669,791 →
Bicyclic Nonane and Decane Compounds Having Dopamine Receptor Affinity
Patent: 5,703,072 →
Application: 08/625,358 →
N-Methyl Piperazine Compounds Having Dopamine Receptor Affinity
Patent: 5,700,445 →
Application: 08/354,905 →
Treatment of Cytomegalovirus Infection
Patent: 5,633,230 →
Application: 08/332,518 →
Anti-Viral Guanidino-Substituted Compounds
Patent: 5,627,194 →
Application: 08/322,492 →
5-HT2 Receptor Ligands
Patent: 5,602,124 →
Application: 08/354,765 →
Alkyl-Substituted Compounds Having Dopamine Receptor Affinity
Patent: 5,602,121 →
Application: 08/354,793 →
Benzyl-Substituted Compounds Having Dopamine Receptor Affinity
Patent: 5,602,120 →
Application: 08/354,766 →
Bone-Stimulating, Non-Vasoactive Parathyroid Hormone Variants
Patent: 5,599,792 →
Application: 08/332,453 →
Kainate-Binding, Human Cns Receptors of the EAA4 Family
Patent: 5,574,144 →
Application: 07/903,456 →
Muscarinic Receptor Ligands
Patent: 5,561,127 →
Application: 08/358,471 →
5-Ht-1D Receptor Ligands
Patent: 5,504,101 →
Application: 08/238,823 →
Parathyroid Hormone Formulation
Patent: 5,496,801 →
Application: 08/172,206 →
Antiviral Polynucleotide Conjugates
Patent: 5,495,006 →
Application: 08/024,254 →
Dna Encoding Variants of Human Corticosteroid Binding Globulin
Patent: 5,432,080 →
Application: 07/994,423 →
Method for Isolating a Soluble Osteogenic Factor from Bone
Patent: 5,403,825 →
Application: 07/937,744 →
Stability-Enhanced Variants of Parathyroid Hormone
Patent: 5,382,658 →
Application: 07/863,014 →
Pharmaceutical Compositions for Use in Treating Inflammation
Patent: 5,344,819 →
Application: 07/829,954 →
Ultrapure Human Interleukin-6
Patent: 5,338,834 →
Application: 08/009,973 →
Method of Purifying Human Epidermal Growth Factor
Patent: 5,290,920 →
Application: 07/869,176 →
Egf Variants and Pharmaceutical Use Thereof
Patent: 5,218,093 →
Application: 07/317,467 →
Recombinant Dna System for Aspergillus
Patent: 5,171,672 →
Application: 07/401,319 →
Isolated Osteogenic Factor
Patent: 5,169,837 →
Application: 07/676,179 →
Vinblastine Synthesis
Patent: 5,034,320 →
Application: 07/032,459 →
Pharmaceutical Compositions and Use Thereof in Treating Inflammation
Patent: 4,997,814 →
Application: 07/204,356 →
Treating Inflammation with Hepatocyte Stimulating Factor Interferon Beta 2
Patent: 4,973,478 →
Application: 07/075,809 →
Shuttle Vectors from Rhodococcus Equi
Patent: 4,920,054 →
Application: 06/889,204 →
Enzymatic Preparation of 3',4'-Anhydrovinblastine
Patent: 4,918,011 →
Application: 06/893,018 →
Process for Extracting Methylxanthines from Aqueous Solutions Containing Same
Patent: 4,904,773 →
Application: 07/023,619 →
Aspergillus Niger Transformation System
Patent: 4,885,249 →
Application: 06/678,578 →
Fermentation Vessels
Patent: 4,847,203 →
Application: 07/090,906 →
Extraction of Alkaloids of Catharanthus Roseus Tissue
Patent: 4,831,133 →
Application: 07/045,621 →
Production of Alkaloid Dimers Using Ferric Ion
Patent: 4,778,885 →
Application: 06/908,991 →
Device for Performing Immunochemical Assays
Patent: 4,729,875 →
Application: 06/880,948 →
Device for Performing Enzyme Immunoassays
Patent: 4,690,801 →
Application: 06/870,320 →
Related Assignments (6)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Mar 15, 2010
From: SANGUINETTI, ELIZABETH L; MARRIOTT, THOMAS B; LOPANSRI, JENNIFER; BLOSCH, CONSUELO M
To: NPS ALLELIX CORP
Reel/Frame 024081/0573 →
Change of Name Dec 23, 2016
From: NPS PHARMACEUTICALS, INC.
To: SHIRE-NPS PHARMACEUTICALS, INC.
Reel/Frame 041187/0545 →
Change of Name Jan 23, 2017
From: NPS PHARMACEUTICALS, INC.
To: SHIRE-NPS PHARMACEUTICALS, INC.
Reel/Frame 041069/0687 →
Change of Name Jan 23, 2017
From: NPS PHARMACEUTICALS, INC.
To: SHIRE-NPS PHARMACEUTICALS, INC.
Reel/Frame 041069/0898 →
Change of Address Jul 19, 2018
From: SHIRE-NPS PHARMACEUTICALS, INC.
To: SHIRE-NPS PHARMACEUTICALS, INC.
Reel/Frame 046598/0592 →
Change of Address Jul 19, 2018
From: SHIRE-NPS PHARMACEUTICALS, INC.
To: SHIRE-NPS PHARMACEUTICALS, INC.
Reel/Frame 046612/0742 →